CLEVELAND, July 8, 2016 /PRNewswire/ -- University Hospitals Case Medical Center is among the first in the country –
On July 8, University Hospitals (UH) implanted its first Absorb dissolving stent on a patient with coronary artery disease. There are only 50 sites around the nation who will launch the Absorb product and UH is the only hospital in Ohio.
Recently approved by the FDA, Absorb is the first and only fully dissolving stent approved for the treatment of coronary artery disease which impacts over 15 million people in the United States and is the world's leading cause of death.
Made of naturally dissolving material, the new device provides the same benefits as traditional stents and trial data supports its potential benefits in restoring long-term vessel function. The stent utilizes the same cath lab equipment already in place and study data supports comparable healing with the traditional metallic stent.
Hiram Bezerra, MD, and Gui Attizzani, MD, of the UH Harrington Heart & Vascular Institute, played a significant role in assisting Abbott in bringing this technology to market.
"Absorb is a new, potentially game-changing therapy for coronary artery disease," said Dr. Bezerra, Medical Director, Cardiovascular Imaging Core Laboratory – UH Harrington Heart & Vascular Institute. "While it may never totally replace traditional DES, this novel technology gives us the ability to repair a patient's artery with comparable healing and safety and reduces long-term complications."
Like traditional metallic drug-eluding stents (DES), Absorb opens a patient's blocked artery but then disappears after leaving no metal behind to restrict natural vessel motion. Absorb is made of polyactic acid similar to material used in dissolving sutures. Through the process of hydrolysis, the scaffold is metabolized after two to three years.
In clinical studies conducted throughout the world, the new Absorb stent demonstrated comparable short-term and mid-term outcomes compared to the leading metallic stent. After the first year of the clinical trial of approximately 2,000 patients in the United States (Absorb III randomized trial) patients who received the Absorb experienced comparable rates of specific adverse events in the intended patient population.
It also eliminates the need for layer upon layer of metal in a situation where patients experience in-stent restenosis. Additionally it reduces the amount of metal in the coronary arteries when the patient requires multiple stents.
"The device restores vasomotor function and pulsatility allowing the artery to move and more naturally regulate blood flow," says Dr. Bezerra, who is Assistant Professor, Medicine, Case Western Reserve University School of Medicine. "It also avoids the long-term future complications related to metallic stents, such as inability to graft to a fully stented artery in the event that a patient needs coronary artery bypass grafting."
Drs. Bezerra and Attizzani have both been involved with the imaging core lab for Absorb studies around the world. While studying structural cardiology in Italy, Dr. Attizzani, a Clinical Assistant Professor, Medicine, CWRU School of Medicine, also had opportunity to implant hundreds of Absorb BVS and participate in European studies of the device. The device has been widely used in Europe for about five years.
Abbott is using Dr. Bezerra's imaging expertise to teach and train staff and physicians around the world about the importance of vascular imaging and why it makes a difference in the proper deployment technique for Absorb.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/university-hospitals-case-medical-center-cardiologists-first-to-implant-abbott-absorb-stent-in-midwest-300296135.html
SOURCE University Hospitals Case Medical Center
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All